Sponsors Should Hang Tight On “New Paradigm” Switch – CDER’s Leonard-Segal

The director of FDA’s Division of Nonprescription Clinical Evaluation advises firms to wait to submit Rx-to-OTC switch applications until the regulations are revised to allow for expanded conditions of safe nonprescription use.